Pietro Pratesi
Overview
Explore the profile of Pietro Pratesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
2
Citations
2
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
PSMC6 regulation of ovarian cancer cisplatin resistance unravels a new mode for proteasome targeting
Costantino M, Mirra L, Darcy P, Corno C, Carenini N, Corna E, et al.
Int J Biol Sci
. 2025 Mar;
21(5):2258-2274.
PMID: 40083690
Ovarian carcinoma has still a poor prognosis. CRISPR/Cas9 loss-of-function screen revealed a relationship between the PSMC6 proteasome subunit expression and survival of cisplatin-sensitive and -resistant ovarian carcinoma cells. Increased levels...
2.
Tosoni B, Naghshineh E, Zanin I, Gallina I, Di Pietro L, Cleris L, et al.
Nucleic Acids Res
. 2025 Feb;
53(4).
PMID: 39970293
Well-differentiated/dedifferentiated liposarcomas (WD/DDLPSs) account for ∼60% of all liposarcomas. They have a poor prognosis due to limited therapeutic options. WD/DDLPSs are characterized by aberrant expression of mouse double minute 2...
3.
Tosoni B, Naghshineh E, Zanin I, Gallina I, Di Pietro L, Cleris L, et al.
Nucleic Acids Res
. 2025 Feb;
53(4).
PMID: 39945321
Well-differentiated/dedifferentiated liposarcomas (WD/DDLPSs) account for ∼60% of all liposarcomas. They have a poor prognosis due to limited therapeutic options. WD/DDLPSs are characterized by aberrant expression of mouse double minute 2...
4.
Bongiorno R, Lecchi M, Botti L, Bosco O, Ratti C, Fontanella E, et al.
Cell Death Dis
. 2024 Sep;
15(9):709.
PMID: 39349458
Breast cancer is the most frequent type of tumor in women and is characterized by variable outcomes due to its heterogeneity and the presence of many cancer cell-autonomous and -non-autonomous...
5.
Nyssen O, Pratesi P, Spinola M, Jonaitis L, Perez-Aisa A, Vaira D, et al.
Antibiotics (Basel)
. 2023 Sep;
12(9).
PMID: 37760723
The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line...